Drug
Raltegravir (ISENTRESS™)
Raltegravir (ISENTRESS™) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_3
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)
NCT01930045
completedphase_3
Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
NCT01114425
completed
A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women
NCT00774683
Clinical Trials (3)
Showing 3 of 3 trials
NCT01930045Phase 1
A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)
NCT01114425Phase 3
Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
NCT00774683
A Pilot Study to Characterize the Pharmacokinetics of Raltegravir in the Cervicovaginal Fluids of HIV-infected Women
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3